ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 1.83 USD 4.57% Market Closed
Market Cap: 176.9m USD

Relative Value

The Relative Value of one ADCT stock under the Base Case scenario is 4.91 USD. Compared to the current market price of 1.83 USD, ADC Therapeutics SA is Undervalued by 63%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADCT Relative Value
Base Case
4.91 USD
Undervaluation 63%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
48
vs Industry
75
Median 3Y
2.3
Median 5Y
2
Industry
7.5
Forward
2.4
vs History
vs Industry
Median 3Y
-1
Median 5Y
-2.4
Industry
21.4
Forward
-1.1
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-2.6
Industry
21.1
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-2
Industry
23.5
vs History
vs Industry
52
Median 3Y
-0.9
Median 5Y
4.4
Industry
2.4
vs History
44
vs Industry
56
Median 3Y
3.6
Median 5Y
2.8
Industry
7.3
Forward
4.6
vs History
42
vs Industry
57
Median 3Y
3.8
Median 5Y
2.5
Industry
8.8
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.4
Industry
4.3
Forward
-2.4
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-2.4
Industry
4
Forward
-2.4
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-3.4
Industry
6.1
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-3.4
Industry
4.1
vs History
53
vs Industry
23
Median 3Y
4.5
Median 5Y
7.5
Industry
4.4

Multiples Across Competitors

ADCT Competitors Multiples
ADC Therapeutics SA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
ADC Therapeutics SA
NYSE:ADCT
176.9m USD 1.4 -0.5 -1.3 -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 563 372.2 -183 286 -222 567.5 -220 027.8
US
Abbvie Inc
NYSE:ABBV
303.2B USD 5.5 59.7 14.9 23
US
Amgen Inc
NASDAQ:AMGN
146.3B USD 4.5 34.6 16.4 31.1
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 4 908.2 10.1 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.8B USD 10.2 -226.7 22.4 23.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 826.8 -466.2 -507.7 -494.1
AU
CSL Ltd
ASX:CSL
132.7B AUD 5.6 31.2 19.4 24.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75B USD 5.4 16.1 14.6 16.2
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -54 -57.9 -52.3
NL
argenx SE
XBRU:ARGX
38.1B EUR 17.9 -347.5 -165.3 -107.6
P/S Multiple
Revenue Growth P/S to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/S: 3 505 933.7
1.4
18%
0.1
FR
Pharnext SCA
OTC:PNEXF
38 563 372.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.5
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
8%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
4
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
1 826.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
53%
0.3
P/E Multiple
Earnings Growth PEG
CH
ADC Therapeutics SA
NYSE:ADCT
Average P/E: 209.9
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -183 286 N/A N/A
US
Abbvie Inc
NYSE:ABBV
59.7
72%
0.8
US
Amgen Inc
NASDAQ:AMGN
34.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
908.2
21%
43.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -226.7
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -466.2 N/A N/A
AU
CSL Ltd
ASX:CSL
31.2
18%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
13%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -347.5 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBITDA: 16.3
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 567.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.4
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.7 N/A N/A
AU
CSL Ltd
ASX:CSL
19.4
12%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -165.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
ADC Therapeutics SA
NYSE:ADCT
Average EV/EBIT: 21.3
Negative Multiple: -1.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 027.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
24%
1
US
Amgen Inc
NASDAQ:AMGN
31.1
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.6
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.1
16%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
12%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -107.6 N/A N/A